AstraZeneca Reports Strong FY25 Results, Positive 2026 Guidance, and Key Pipeline Progress
AZN sits 58% above its 52-week low of $122.26 on elevated volume (4.3× avg).
Summary
AstraZeneca PLC announced robust financial results for fiscal year 2025, with strong revenue and core EPS growth, and provided positive guidance for 2026, alongside significant pipeline advancements and a favorable patent ruling for Enhertu.
Key Events · Earnings and Guidance · AZN
-
Strong FY 2025 Financial Performance
Total Revenue increased by 8% at constant exchange rates (CER) to $58.7 billion, and Core EPS grew by 11% (CER) to $9.16, demonstrating robust growth across key therapy areas.
-
Positive FY 2026 Guidance Issued
The company expects Total Revenue to increase by a mid-to-high single-digit percentage and Core EPS to increase by a low double-digit percentage in 2026, both at CER.
-
Major Enhertu Patent Victory
The US Court of Appeals for the Federal Circuit found Seagen's Enhertu patent invalid, vacating a prior judgment and damages award, which removes a significant legal and financial liability.
-
Significant Pipeline Advancements
AstraZeneca achieved 16 positive Phase 3 readouts and 43 major regulatory approvals in 2025, including promising Phase IIb results for elecoglipron in obesity and type 2 diabetes, supporting its progression to Phase III.
Analysis · AZN · Life Sciences
AstraZeneca PLC delivered robust financial results for fiscal year 2025, with total revenue increasing by 8% at constant exchange rates (CER) to $58.7 billion and Core EPS growing by 11% (CER) to $9.16. The company also issued positive guidance for fiscal year 2026, projecting mid-to-high single-digit revenue growth and low double-digit Core EPS growth (CER). A significant positive development is the US Court of Appeals' decision finding Seagen's Enhertu patent invalid, which vacates a prior damages award and royalty obligations, removing a substantial financial and legal overhang. The company's pipeline continued to deliver with 16 positive Phase 3 readouts and 43 major approvals in 2025, including promising Phase IIb results for elecoglipron in obesity and type 2 diabetes, supporting its progression to Phase III. However, there were some pipeline setbacks, including the discontinuation of the TROPION-Lung12 (Datroway) and LATIFY (ceralasertib + Imfinzi) Phase 3 trials, and the decision not to pursue regulatory filings for Lynparza DUO-O. Additionally, the company faces ongoing legal challenges, notably an indictment in China related to personal information infringement and illegal trade, and the Anti-Terrorism Act lawsuit in the US proceeding to District Court. Despite these challenges, the robust financial performance, optimistic outlook, and the major patent victory for a key oncology drug position AstraZeneca strongly.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $193.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $299.6B. The 52-week trading range was $122.26 to $195.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.